Literature DB >> 34022330

Prospective surveillance for invasive Staphylococcus aureus and group A Streptococcus infections in a setting with high community burden of scabies and impetigo.

Li Jun Thean1, Adam Jenney2, Daniel Engelman3, Lucia Romani4, Handan Wand4, Jyotishna Mani5, Jessica Paka5, Tuliana Cua5, Sera Taole5, Vika Soqo6, Aalisha Sahukhan6, Mike Kama6, Meciusela Tuicakau6, Joseph Kado7, Natalie Carvalho8, Margot Whitfeld9, John Kaldor4, Andrew C Steer3.   

Abstract

BACKGROUND: Invasive Staphylococcus aureus (iSA) and group A Streptococcus (iGAS) impose significant health burdens globally. Both bacteria commonly cause skin and soft tissue infections (SSTIs), which can result in invasive disease. Understanding of the incidence of iSA and iGAS remains limited in settings with a high SSTI burden.
METHODS: Prospective surveillance for admissions with iSA or iGAS was conducted at the referral hospital in Fiji's Northern Division over 48 weeks between July 2018 and June 2019.
RESULTS: There were 55 admissions for iSA and 15 admissions for iGAS (incidence 45.2 and 12.3 per 100,000 person-years, respectively). The highest incidence was found in patients aged ≥65 years (59.6 per 100,000 person-years for iSA and iGAS). The incidence of iSA was higher in indigenous Fijians (iTaukei) (71.1 per 100,000 person-years) compared with other ethnicities (incidence rate ratio 9.7, 95% confidence interval 3.5-36.9). SSTIs were found in the majority of cases of iSA (75%) and iGAS (53.3%). Thirteen of the 14 iGAS strains isolated belonged to emm cluster D (n = 5) or E (n = 8). The case fatality rate was high for both iSA (10.9%) and iGAS (33.3%).
CONCLUSIONS: The incidence of iSA and iGAS in Fiji is very high. SSTIs are common clinical foci for both iSA and iGAS. Both iSA and iGAS carry a substantial risk of death. Improved control strategies are needed to reduce the burden of iSA and iGAS in Fiji.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Group A Streptococcus; Invasive infections; Skin and soft tissue infection; Staphylococcus aureus; Streptococcus pyogenes

Year:  2021        PMID: 34022330     DOI: 10.1016/j.ijid.2021.05.041

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  4 in total

1.  Case Report: Therapeutic Strategy With Delayed Debridement for Culture-Negative Invasive Group A Streptococcal Infections Diagnosed by Metagenomic Next-Generation Sequencing.

Authors:  Wenfang He; Chenfang Wu; Yanjun Zhong; Jinxiu Li; Guyi Wang; Bo Yu; Ping Xu; Yiwen Xiao; Tiantian Tang
Journal:  Front Public Health       Date:  2022-05-11

2.  Prevention of bacterial complications of scabies using mass drug administration: A population-based, before-after trial in Fiji, 2018-2020.

Authors:  Li Jun Thean; Lucia Romani; Daniel Engelman; Handan Wand; Adam Jenney; Jyotishna Mani; Jessica Paka; Tuliana Cua; Sera Taole; Maciu Silai; Komal Ashwini; Aalisha Sahukhan; Mike Kama; Meciusela Tuicakau; Joseph Kado; Matthew Parnaby; Natalie Carvalho; Margot Whitfeld; John Kaldor; Andrew C Steer
Journal:  Lancet Reg Health West Pac       Date:  2022-03-22

3.  Standardization of Epidemiological Surveillance of Group A Streptococcal Impetigo.

Authors:  Kate M Miller; Jonathan R Carapetis; Thomas Cherian; Roderick Hay; Michael Marks; Janessa Pickering; Jeffrey W Cannon; Theresa Lamagni; Lucia Romani; Hannah C Moore; Chris A Van Beneden; Dylan D Barth; Asha C Bowen
Journal:  Open Forum Infect Dis       Date:  2022-09-15       Impact factor: 4.423

4.  Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis.

Authors:  Susanna J Lake; John M Kaldor; Myra Hardy; Daniel Engelman; Andrew C Steer; Lucia Romani
Journal:  Clin Infect Dis       Date:  2022-09-29       Impact factor: 20.999

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.